PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.121
https://www.valueinhealthjournal.com/article/S1098-3015(18)33421-1/fulltext
Title :
PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33421-1&doi=10.1016/j.jval.2018.09.121
First page :
Section Title :
Open access? :
No
Section Order :
642